Circulating 25-hydroxyvitamin D and lung cancer risk and survival: A dose-response meta-analysis of prospective cohort studies.
Circulating 25-hydroxyvitamin D and lung cancer risk and survival: A dose-response meta-analysis of prospective cohort studies.
复制标题
DOI：
10.1097/md.0000000000008613
复制
发表时间：
2017-11
期刊：
影响因子：
1.6
通讯作者：
Ma J
中科院分区：
文献类型：
--
作者：
Feng Q;Zhang H;Dong Z;Zhou Y;Ma J
补充数字内容可在文本中获得血清25-羟基维生素D水平较低与几个负面结果有关。然而，以前的研究表明，25-羟基维生素D与肺癌风险和生存率有关，但结果存在争议。检索了PubMed和Embase数据库，更新至2017年8月，以确定和量化25-羟基维生素D与肺癌风险和生存率之间的潜在关联。本荟萃分析纳入了17项合格研究，共涉及138，858例受试者和4368例事件病例。我们的研究结果显示25-羟基维生素D与肺癌风险和死亡率之间存在统计学显著相关性。然而，循环中的25-羟基维生素D与肺癌的总体生存率无关。此外，与最低循环25-羟基维生素D相比，最高循环25-羟基维生素D显著降低男性和女性患肺癌的风险。此外，在高加索人和亚洲人中，最高循环25-羟基维生素D与较低的风险显著相关。我们还在分段回归分析中获得了10 nmol/L拐点处的最佳拟合，增加10 nmol/L循环25-羟基维生素D剂量与肺癌风险降低8%和肺癌死亡率风险降低7%相关。研究质量、参与者数量和病例数量的亚组荟萃分析显示与主要结果一致。最高的循环25-羟基维生素D与降低肺癌风险和死亡率相关，但与总生存率无关
Supplemental Digital Content is available in the text Lower serum level of 25-hydroxyvitamin D is associated with several negative outcomes. However, previous studies have indicated that 25-hydroxyvitamin D is associated with lung cancer risk and survival, but presented controversial results. PubMed and Embase databases were searched update to August 2017 to identify and quantify the potential association between 25-hydroxyvitamin D and lung cancer risk and survival. Seventeen eligible studies involving a total of 138,858 participants with 4368 incident cases were included in this meta-analysis. Our results showed statistically significant association between 25-hydroxyvitamin D and lung cancer risk and mortality. However, circulating 25-hydroxyvitamin D was not associated with overall lung cancer survival. Furthermore, compared with the lowest circulating 25-hydroxyvitamin D, the highest circulating 25-hydroxyvitamin D is significantly decreased risk of lung cancer risk in male and female. In addition, the highest circulating 25-hydroxyvitamin D was significantly associated with a lower risk in Caucasian and Asian. We also obtained the best fit at an inflection point of 10 nmol/L in piecewise regression analysis, increasing 10 nmol/L dose of circulating 25-hydroxyvitamin D was associated with an 8% reduction in the risk of lung cancer risk and an 7% reduction in the risk of lung cancer mortality. Subgroup meta-analyses in study quality, number of participants, and number of cases showed consistent with the primary findings. The highest circulating 25-hydroxyvitamin D was associated with decreased lung cancer risk and mortality but not overall survival